ALK-Abello Overview

  • Year Founded
  • 1923

Year Founded

  • Status
  • Public

  • Employees
  • 2,759

Employees

  • Stock Symbol
  • ALK B

Stock Symbol

  • Investments
  • 12

  • Share Price
  • $35.96
  • (As of Thursday Closing)

ALK-Abello General Information

Description

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Contact Information

Website
www.alk.net
Formerly Known As
Diagnoselaboratoriet Af 1977 A/S
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Boge Alle 6-8
  • 2970 Horsholm
  • Denmark
+45 45
Primary Industry
Clinics/Outpatient Services
Stock Exchange
CSE
Corporate Office
  • Boge Alle 6-8
  • 2970 Horsholm
  • Denmark
+45 45

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ALK-Abello Stock Performance

As of 19-Nov-2026, ALK-Abello’s stock price is $35.96. Its current market cap is $7.98B with 222M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$35.96 $35.74 $29.41 - $42.20 $7.98B 222M 231K $0.98

ALK-Abello Financials Summary

As of 30-Sep-2026, ALK-Abello has a trailing 12-month revenue of $1.1B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,478,621 7,948,712 4,918,226 3,399,317
Revenue 1,098,175 953,652 803,170 700,048
EBITDA 343,151 302,775 199,886 137,572
Net Income 218,298 180,849 118,220 70,527
Total Assets 1,554,924 1,424,303 1,150,455 998,622
Total Debt 72,513 65,735 165,606 113,581
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ALK-Abello Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ALK-Abello‘s full profile, request access.

Request a free trial

ALK-Abello Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ALK-Abello Investments & Acquisitions (12)

ALK-Abello’s most recent deal was a Seed Round with Allegria Therapeutics for . The deal was made on 11-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Allegria Therapeutics 11-Dec-2025 Seed Round Other Pharmaceuticals and Biotechnology
Allerquest 02-Jan-2024 Merger/Acquisition Clinics/Outpatient Services
Otonomy (Otiprio Fluoroquinolone Antibacterial) 28-May-2021 Corporate Asset Purchase Pharmaceuticals
Betamab Therapeutics 20-Apr-2020 Corporate Drug Delivery
Allergy Laboratories 03-Jan-2017 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 12 investments and acquisitions. Get the full list »

ALK-Abello ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

25.89 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view ALK-Abello’s complete esg history, request access »

ALK-Abello Exits (3)

ALK-Abello’s most recent exit was on 12-Feb-2014 from Actt. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Actt 12-Feb-2014 Completed
DBV Technologies 05-Jan-2011 Completed
  • 8 buyers
DBV Technologies 21-Jan-2009 Later Stage VC Completed
  • 4 buyers
To view ALK-Abello’s complete exits history, request access »

ALK-Abello Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Alk-Abelló Nordic Hoersholm, Denmark 2008
Allerquest Monroe, CT 2005
Nelco Vet New York, NY 2001
Alk-Abello' Source Materials Post Falls, ID 1975
Western Allergy Services Victoria, Canada 1972

ALK-Abello FAQs

  • When was ALK-Abello founded?

    ALK-Abello was founded in 1923.

  • Where is ALK-Abello headquartered?

    ALK-Abello is headquartered in Horsholm, Denmark.

  • What is the size of ALK-Abello?

    ALK-Abello has 2,759 total employees.

  • What industry is ALK-Abello in?

    ALK-Abello’s primary industry is Clinics/Outpatient Services.

  • Is ALK-Abello a private or public company?

    ALK-Abello is a Public company.

  • What is ALK-Abello’s stock symbol?

    The ticker symbol for ALK-Abello is ALK B.

  • What is the current stock price of ALK-Abello?

    As of 19-Nov-2026 the stock price of ALK-Abello is $35.96.

  • What is the current market cap of ALK-Abello?

    The current market capitalization of ALK-Abello is $7.98B.

  • What is ALK-Abello’s current revenue?

    The trailing twelve month revenue for ALK-Abello is $1.1B.

  • What is ALK-Abello’s annual earnings per share (EPS)?

    ALK-Abello’s EPS for 12 months was $0.98.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process